TABLE 3.
Variable | OR (95% CI) | P |
---|---|---|
Age | 1.0 (0.96 to 1.05) | 0.90 |
Male sex | 1.0 (0.3 to 3.4) | 0.90 |
Diabetes mellitus | 0.2 (0.03 to 1.8) | 0.16 |
Proton pump inhibitor | 0.6 (0.2 to 1.8) | 0.40 |
Peripheral blood leukocytes, ×109/L | 1.0 (0.9 to 1.1) | 1 |
Model for End-stage Liver Disease | 1.08 (0.997 to 1.16) | 0.06 |
Creatinine at diagnosis, μmol/L | 1.005 (1.000 to 1.011) | 0.05 |
Ascites leukocyte count | 1.0 (1.0 to 1.0) | 0.70 |
Ascites neutrophil count | 1.0 (1.0 to 1.0) | 0.60 |
Mode of infection acquisition | ||
Community | 1 | – |
Health care | 2.4 (0.4 to 12.9) | 0.32 |
Nosocomial | 8.1 (1.4 to 45.8) | 0.02 |
Nosocomial | 4.6 (1.3 to 15.4) | 0.015 |
Any antibiotic exposure within 30 days | 2.1 (0.6 to 7.2) | 0.25 |
Fluoroquinolone prophylaxis | 1.5 (0.4 to 6.3) | 0.60 |
Exposure to broad-spectrum antibiotics ± fluoroquinolone within 30 days | 4.9 (0.9 to 27) | 0.07 |